All News

MMWR: Monkeypox Outbreak in Nine States

Save

d MMWR

Jun 10, 2022

CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area; current epidemiology suggests person-to-person community spread.

Read Article

EULAR 2022 Top 10 Abstracts (6.10.2022)

Save

d Jack Cush, MD

Jun 10, 2022

Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty.

Read Article

CV risk factors not equal when considering magnitude of risk

Save

d Janet Pope, MD, MPH, FRCPC

Jun 10, 2022

What can we learn from Oral Surveillance?

The Oral Surveillance trial has almost become a household word for rheumatologists.

Read Article

Can we stop RA before it happens?

Save

d David Liew, FRACP

Jun 09, 2022

Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals.

Read Article

Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more. https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ

Links:

https://bit.ly/3aKmeUM

Dr. John Cush RheumNow ( View Tweet)

Jun 12, 2022

Getting Real on PMR Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG

Links:

https://bit.ly/3xB1J5T

Dr. John Cush RheumNow ( View Tweet)

Jun 11, 2022

Polymyalgia rheumatica immunological puzzle further illustrated Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022. https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t

Links:

https://bit.ly/3NJ7O5Q

Dr. John Cush RheumNow ( View Tweet)

Jun 11, 2022

Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit

Links:

https://bit.ly/3HaBAhm

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p

Links:

https://bit.ly/3Hc7gmv

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Miss this week's TNR? Watch the playback. https://t.co/LSlw939Vj2 https://t.co/K62afKWz95

Links:

https://bit.ly/3O4dgAe

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Can we stop RA before it happens? Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals. https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT

Links:

https://bit.ly/3MvX0Xu

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Price of a newly launched drug increased from $2115 per year in 2008 to $180 007 per year in 2021. In 2008 only 9% of drug cost >$150k/yr; this rose to 47% by 2021. Greater increases seen w/ biologics, rare disease and nononcology drugs https://t.co/JaGzNqCxdF

Links:

https://bit.ly/3zLZbDJ

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Gout Undertreatment Persists Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels. https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10

Links:

https://bit.ly/3NDMLBM

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR

Links:

https://bit.ly/3mvNjOj

Dr. John Cush RheumNow ( View Tweet)

Jun 10, 2022

Video: Residual Pain in RA Dr. Maxime Dougados discusses OP0052 at #EULAR2022. https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW

Links:

https://bit.ly/3H6I7d8

Dr. John Cush RheumNow ( View Tweet)

Jun 09, 2022

Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD

Links:

https://bit.ly/3xuHqHk

Dr. John Cush RheumNow ( View Tweet)

Jun 09, 2022

#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Jun 09, 2022

Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE

Links: